| Literature DB >> 26277695 |
Chelsea Carpenter1, John Sidney1, Ravi Kolla1, Kaustuv Nayak2, Helena Tomiyama3, Claudia Tomiyama3, Oscar A Padilla3, Virginie Rozot4, Syed F Ahamed5, Carlos Ponte6, Valeria Rolla6, Paulo R Antas6, Anmol Chandele2, John Kenneth5, Seetha Laxmi7, Edward Makgotlho4, Valentina Vanini8, Giuseppe Ippolito8, Alexandra S Kazanova9, Alexander V Panteleev9, Willem Hanekom4, Harriet Mayanja-Kizza10, David Lewinsohn11, Mayuko Saito12, M Juliana McElrath13, W Henry Boom14, Delia Goletti8, Robert Gilman15, Irina V Lyadova9, Thomas J Scriba4, Esper G Kallas3, Kaja Murali-Krishna16, Alessandro Sette1, Cecilia S Lindestam Arlehamn17.
Abstract
We compared T cell recognition of 59 prevalently recognized Mycobacterium tuberculosis (MTB) antigens in individuals latently infected with MTB (LTBI), and uninfected individuals with previous BCG vaccination, from nine locations and populations with different HLA distribution, MTB exposure rates, and standards of TB care. This comparison revealed similar response magnitudes in diverse LTBI and BCG-vaccinated cohorts and significant correlation between responses in LTBIs from the USA and other locations. Many antigens were uniformly recognized, suggesting suitability for inclusion in vaccines targeting diverse populations. Several antigens were similarly immunodominant in LTBI and BCG cohorts, suggesting applicability for vaccines aimed at boosting BCG responses. The panel of MTB antigens will be valuable for characterizing MTB-specific CD4 T cell responses irrespective of ethnicity, infecting MTB strains and BCG vaccination status. Our results illustrate how a comparative analysis can provide insight into the relative immunogenicity of existing and novel vaccine candidates in LTBIs.Entities:
Keywords: BCG; CD4; LTBI; T cell antigen; Tuberculosis; Vaccine
Mesh:
Substances:
Year: 2015 PMID: 26277695 PMCID: PMC4666753 DOI: 10.1016/j.tube.2015.07.001
Source DB: PubMed Journal: Tuberculosis (Edinb) ISSN: 1472-9792 Impact factor: 3.131